(Q40513934)

21 September 2017

title

An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting (English)

1 reference

21 September 2017

1 reference

A J Palmer

1

1 reference

21 September 2017

L Annemans

2

1 reference

21 September 2017

S Roze

3

1 reference

21 September 2017

M Lamotte

4

1 reference

21 September 2017

R A Rodby

5

1 reference

21 September 2017

R W Bilous

6

1 reference

21 September 2017

language of work or name

1 reference

1 October 2004

1 reference

Journal of Human Hypertension

21 September 2017

published in

1 reference

21 September 2017

volume

18

1 reference

21 September 2017

issue

10

1 reference

21 September 2017

page(s)

733-738

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.jhh.1001729

21 September 2017

exact match

0 references

cites work

Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001729

Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001729

Clinical outcomes, quality of life, and costs in the North Thames Dialysis Study of elderly people on dialysis: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001729

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001729

The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001729

An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001729

Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001729

An economic model of the long-term health care burden of Type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001729

The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001729

[Increased clinical and economic advantages using PROSIT (proteinuria screening and intervention) in type 2 diabetic patients].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001729

Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001729

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001729

Induction of p27KIP1 after unilateral ureteral obstruction is independent of angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001729

Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001729

Estimating country-specific cost-effectiveness from multinational clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001729

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001729

Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001729

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001729

Primer on Medical Decision Analysis: Part 5—Working with Markov Processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001729

The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001729

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.JHH.1001729

1 reference

Dimensions Publication ID

21 September 2017

1045044303

0 references

1 reference